Drug intelligence / Profile preview

ENERGI-F707

Development stage: Preclinical
Lead developer: Energenesis Biomedical
Modality: Small Molecules
Administration: Topical, Oral

Overview

ENERGI-F707 is a small molecule drug under preclinical development as an agonist of AMP-activated protein kinase (AMPK). It is part of a series of AMPK activators derived from herbal sources and is being investigated primarily for the treatment of mitochondrial diseases and other metabolic or neurodegenerative disorders. The mechanism of action involves stimulation (agonism) of AMPK, a key regulator in cellular energy homeostasis. The drug has not yet reached clinical trials and remains in the preclinical stage. Development efforts have been led by Energenesis Biomedical, with HuaAn Fund Management Co., Ltd. also listed as an originator organization[1][2][3].

Other names: ENERGI F707

Targets

AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on ENERGI-F707.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENERGI-F707.

Explore the full profile